Osimertinib's Benefits in NSCLC Can Extend Beyond First Line – Medscape

Written by

admin

in

  1. Osimertinib’s Benefits in NSCLC Can Extend Beyond First Line  Medscape
  2. Astra’s Lung Cancer Combination Boosted Survival in Key Study  Bloomberg
  3. AstraZeneca escalates EGFR lung cancer rivalry with J&J as Tagrisso combo posts survival win  Fierce Pharma
  4. WCLC 2025 Highlights: FLAURA2 trial  Oncodaily
  5. TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer  AstraZeneca US

Continue Reading

More posts